Cardiff Oncology Stock Beta
| CRDF Stock | USD 4.03 0.06 1.51% |
Cardiff Oncology fundamentals help investors to digest information that contributes to Cardiff Oncology's financial success or failures. It also enables traders to predict the movement of Cardiff Stock. The fundamental analysis module provides a way to measure Cardiff Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cardiff Oncology stock.
Cardiff | Beta |
Cardiff Oncology Company Beta Analysis
Cardiff Oncology's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Cardiff Oncology Beta | 1.93 |
Most of Cardiff Oncology's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cardiff Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cardiff Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Cardiff Oncology is extremely important. It helps to project a fair market value of Cardiff Stock properly, considering its historical fundamentals such as Beta. Since Cardiff Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cardiff Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cardiff Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Cardiff Oncology has a Beta of 1.928. This is 124.19% higher than that of the Biotechnology sector and 38.71% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Cardiff Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cardiff Oncology's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cardiff Oncology could also be used in its relative valuation, which is a method of valuing Cardiff Oncology by comparing valuation metrics of similar companies.Cardiff Oncology is currently under evaluation in beta category among its peers.
Cardiff Oncology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cardiff Oncology from analyzing Cardiff Oncology's financial statements. These drivers represent accounts that assess Cardiff Oncology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cardiff Oncology's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 7.4M | 7.4M | 375.5M | 61.0M | 70.2M | 66.7M | |
| Enterprise Value | (4.0M) | (1.1M) | 245.4M | 47.4M | 54.5M | 51.8M |
Cardiff Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cardiff Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cardiff Oncology's managers, analysts, and investors.Environmental | Governance | Social |
Cardiff Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Cardiff Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cardiff Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cardiff Oncology's value.| Shares | Blair William & Co | 2024-09-30 | 247.1 K | Gsa Capital Partners Llp | 2024-09-30 | 186.7 K | Two Sigma Investments Llc | 2024-09-30 | 184.6 K | Bank Of New York Mellon Corp | 2024-09-30 | 171.1 K | Millennium Management Llc | 2024-09-30 | 152.7 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 143 K | Avestar Capital, Llc | 2024-09-30 | 140.5 K | Charles Schwab Investment Management Inc | 2024-09-30 | 121.3 K | Xtx Topco Ltd | 2024-09-30 | 120.4 K | Blackrock Inc | 2024-09-30 | 2.7 M | Vanguard Group Inc | 2024-09-30 | 2.2 M |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cardiff Oncology will likely underperform.
Cardiff Fundamentals
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (76.37) % | ||||
| Current Valuation | 173.53 M | ||||
| Shares Outstanding | 66.52 M | ||||
| Shares Owned By Insiders | 5.62 % | ||||
| Shares Owned By Institutions | 27.49 % | ||||
| Number Of Shares Shorted | 9.48 M | ||||
| Price To Earning | (0.48) X | ||||
| Price To Book | 4.65 X | ||||
| Price To Sales | 383.87 X | ||||
| Revenue | 488 K | ||||
| Gross Profit | (34.22 M) | ||||
| EBITDA | (45.01 M) | ||||
| Net Income | (41.44 M) | ||||
| Cash And Equivalents | 122.01 M | ||||
| Cash Per Share | 2.82 X | ||||
| Total Debt | 2.15 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 15.02 X | ||||
| Book Value Per Share | 1.01 X | ||||
| Cash Flow From Operations | (30.89 M) | ||||
| Short Ratio | 5.73 X | ||||
| Earnings Per Share | (0.95) X | ||||
| Target Price | 10.75 | ||||
| Number Of Employees | 31 | ||||
| Beta | 1.93 | ||||
| Market Capitalization | 264.1 M | ||||
| Total Asset | 81.64 M | ||||
| Retained Earnings | (339.54 M) | ||||
| Working Capital | 66.97 M | ||||
| Current Asset | 16.9 M | ||||
| Current Liabilities | 4.78 M | ||||
| Net Asset | 81.64 M |
About Cardiff Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cardiff Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardiff Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cardiff Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Check out Cardiff Oncology Piotroski F Score and Cardiff Oncology Altman Z Score analysis. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share | Quarterly Revenue Growth 0.17 | Return On Assets | Return On Equity |
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.